Expert Rev Clin Pharmacol. 2009;2(1):37-53. In Phase I, seven trials were conducted ( Table 2). Except for trial 19.4.107, all Phase I trials were randomized, double-blind, crossover trials in which ...
Sugammadex effectively reverses neuromuscular blockade in myasthenia gravis patients, ensuring rapid recovery and minimal complications. The review of 24 studies with 1679 patients showed no ...
Sugammadex also has demonstrated the ability to reverse the effects of muscle relaxation induced by vecuronium bromide. The most common adverse reactions (incidence >5%) seen with sugammadex in ...
(Reuters) - Merck & Co Inc said it expects its long-delayed drug to reverse the effects of anesthesia to be denied U.S. approval after U.S. regulators said they need to conduct more site inspections ...
Merck’s new drug application resubmission for sugammadex sodium injection has been accepted for review by the FDA. Neuromuscular blockade, which is used by anesthesiologists to relax muscles during ...
Zydus Lifesciences Limited (including its subsidiaries/affiliates, hereafter referred to as Zydus) has received final approval from the United States Food and Drug ...
Case Name: In re Sugammadex, No. 20-CV-2576 (CCC/LDW), 2023 WL 3966146 (D.N.J. June 13, 2023) (Cecchi, J.) Nature of the Case and Issue(s) Presented: In Merck’s consolidated action against various ...
Nature of the Case and Issue(s) Presented: Merck owned U.S. Patent No. 6,670,340 (“the ‘’340 patent”), which issued on Dec. 30, 2003, and claimed a class of 6-mercaptocyclodextrin derivatives, ...
The sugammadex clinical development program included data from 30 worldwide clinical trials in 2054 subjects who received sugammadex. In all of the reported trials made available by the developer, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results